Prof. Vasilev’s journey into this area of research was sparked by a personal experience with peppermint leaves, which provided relief for his sore throat when added to his drink. This observation prompted him to investigate whether the bioactive properties of peppermint could be effectively transformed into a durable, protective coating for medical devices through plasma technology. His expertise, accumulated over two decades of research, laid the groundwork for this novel approach.

The research team, including several prominent scientists, carried out their work in the Biomedical Nanoengineering Laboratory at Flinders University. This collaboration included Professor Vasilev, Associate Professor Vi-Khanh Truong, Dr. Andrew Hayes, and two dedicated PhD candidates, Trong Quan Luu and Tuyet Pham. Together, they created a nanoscale peppermint-oil coating that not only protects against various forms of infection but also offers anti-inflammatory and antioxidant benefits, crucial for maintaining compatibility with human tissue.

The methodology employed by the researchers involved the use of atmospheric pressure plasma, a cutting-edge technique that allowed them to turn peppermint essential oil into an ultra-thin film capable of tightly adhering to a diverse array of medical materials. This plasma-induced polymerization is a pivotal aspect of the coating process, circumventing the need for heat or harmful chemicals, which is often a limitation in other coating methods. By preserving the natural characteristics of the peppermint oil, the researchers have developed a coating that remains effective while ensuring environmental sustainability.

An important milestone in the project’s development was the testing of this innovative coating on urinary catheters, medical devices that have frequently been associated with healthcare-associated infections. As co-author Associate Professor Truong points out, such infections significantly contribute to patient discomfort and increased healthcare costs. The results revealed that the peppermint coating effectively eliminated up to 90% of harmful reactive oxygen species, mitigating tissue damage and irritation.

More impressive still, the coating displayed a strong antibacterial effect against critical pathogens, including Escherichia coli and Pseudomonas aeruginosa. It was found to kill bacteria on contact without releasing any pharmaceutical drugs into the body, which can often present a risk of adverse effects. Furthermore, the peppermint oil coating was shown to enhance bacterial sensitivity to conventional antibiotics, which could play a crucial role in combating antibiotic resistance—a mounting challenge in contemporary healthcare.

The findings from Dr. Andrew Hayes indicated that the peppermint coating modulates the immune response, reducing pro-inflammatory signals while enhancing those associated with healing. This phenomenon aids the body in tolerating medical devices more comfortably, reflecting a critical advancement in how we can improve patient experiences with medical interventions.

Laboratory testing further validated the safety of the coating for human tissue, demonstrating that human cells could grow normally on its surface while maintaining metabolic health. This compatibility creates a strong foundation for the coating’s application to various medical devices, such as those used in orthopedic surgery and long-term clinical care settings.

In addition to its healthcare benefits, the technological process intrinsic to developing this coating aligns with environmentally conscious manufacturing practices. By utilizing renewable peppermint oil and eschewing solvent-based methods, the researchers have crafted a system that has the potential to be powered entirely by renewable sources, marking significant progress in the pursuit of sustainable medical technologies.

The proximity of the Biomedical Nanoengineering Laboratory to Flinders Medical Centre has facilitated productive collaborations between researchers, medical professionals, and nursing staff. These partnerships ensure that the research is clinically relevant, tailored to real-world applications, and ultimately beneficial for patient care.

Moving forward, the team hopes their work will stimulate the advent of a new class of medical coatings that leverage natural compounds to enhance safety outcomes for patients. Their innovative spirit positions them at the forefront of transformational research in biomedical engineering, driven by a commitment to improving patient outcomes.

Ultimately, the researchers at Flinders University are eager to continue developing their peppermint-based technology and are actively seeking opportunities for collaboration with industry partners. Their aim is to transition their findings from the lab to real-world applications, wherein patients can benefit from this exceptional advancement in medical coatings.

In conclusion, the development of a peppermint essential oil coating signifies a remarkable stride towards safer medical devices, aligning natural remedies with cutting-edge biomedical technology. As the study progresses, the implications for increased patient comfort and infection prevention could redefine medical practices, opening up avenues for future research and applications.

Subject of Research: Human tissue samples
Article Title: A Multifunctional Bioactive Nanoscale Coating Deposited by Atmospheric Pressure Plasma Polymerization of Peppermint Essential Oil
News Publication Date: 19-Jan-2026
Web References: DOI link
References: Published in the journal Small
Image Credits: Flinders University

Keywords

Antibacterial coating, peppermint essential oil, plasma technology, medical devices, infection prevention, inflammation, biomedical engineering, human tissue compatibility, sustainable manufacturing, antibiotic resistance

At the helm of this research are Dr. Caitlin Dugdale and Dr. Kimon Zachary, both esteemed physicians in the Division of Infectious Diseases at MGH and assistant professors at Harvard Medical School. Their extensive study is documented in the journal Infection Control and Hospital Epidemiology, where they delve into the methodology behind this innovative risk scoring tool. The study was co-authored by Erica Shenoy, the Chief of Infection Control at Mass General Brigham, whose leadership in infection control adds a vital layer of authority to the project.

Patients exhibiting symptoms suggestive of TB represent a complex challenge for healthcare providers. Protocols require these patients to be placed in airborne infection isolation rooms, which are equipped with specialized air handling systems to prevent the spread of this airborne disease. As such, it is imperative to ascertain whether or not a TB infection is present quickly, in order to optimize the use of isolation facilities and avoid unnecessary burden on hospital resources. The “TB or Not TB” tool aims to streamline this process, enhancing the clinician’s capacity to make prompt, informed decisions regarding patient care while simultaneously alleviating workflow congestion typically associated with isolation procedures.

The foundation of the tool lies in a meticulous review of historical patient data. By examining the records of individuals diagnosed with TB alongside those identified as high-risk who ultimately tested negative, the research team constructed a robust risk scoring model. This model was rigorously validated to ensure its efficacy, allowing for sound clinical judgments regarding the discontinuation of isolation precautions. Such an approach not only boosts the confidence of clinicians in their assessments but also safeguards the wellbeing of patients and healthcare workers alike.

Integration of this tool into the electronic health record systems at MGB sites simplifies its deployment. The designation of “TB-Risk” alerts clinicians to the necessary precautions upon patient admission. Once clinical evaluations are concluded and evidence suggests a low likelihood of TB infection, providers can readily utilize the “TB or Not TB” tool to determine the appropriateness of ending isolation measures. This intuitiveness enhances the practicality of clinical decision-making in urgent scenarios where TB risk is a factor.

What distinguishes this tool further is its impressive prospective analysis capabilities. Over six years, the researchers examined thousands of TB evaluations across the MGB system. The results were illuminating; the tool demonstrated a perfect identification rate for confirmed TB cases, ensuring that no patient who tested positive for TB was prematurely released from isolation. Simultaneously, it indicated a significant number of cases where TB infection was highly improbable, allowing these patients to safely transition from isolation more swiftly.

The implications for clinical workflow are profound. By leveraging the “TB or Not TB” tool, healthcare facilities can address bed capacity issues that often arise from prolonged isolation periods. With efficient patient management, the strain on resources lessens, enabling hospitals to provide more timely care to a greater number of patients. Furthermore, healthcare providers experience reduced administrative burdens, freeing them to concentrate on direct patient care, which ultimately boosts professional satisfaction and wellbeing.

As the tool garners validation and acceptance within the healthcare community, the team behind its development views this as merely the beginning. Future expansions of this approach contemplate the inclusion of additional infectious diseases, thereby broadening the scope of clinical decision support tools available to healthcare providers. The evolution of such technologies reflects the ongoing commitment of medical professionals to enhance patient safety through data-driven decision-making processes.

In summary, the “TB or Not TB” tool exemplifies the intersection of medicine, technology, and patient care, showcasing how innovative approaches in clinical decision support can significantly reshape infection control strategies in healthcare settings. As TB cases continue to pose a challenge in the U.S., this tool stands as a beacon of hope, underscoring the potential for improved patient outcomes through refined clinical assessments and efficient use of isolation protocols.

Today, as healthcare systems strive to respond to infectious disease challenges pragmatically, the success of the “TB or Not TB” tool marks a pivotal stride toward optimizing patient care while upholding stringent safety measures. The initial findings support continued focus on integrating evidence-based tools into clinical practice to achieve superior health outcomes while protecting the interests of both patients and healthcare workers alike.

This new study encourages further research and optimization of infection control tools, fostering a culture of innovation and adaptability in healthcare. As we navigate the complexities of managing infectious diseases, collaboration among experts from various disciplines will prove essential in safeguarding public health and enhancing the quality of care delivered in hospitals across the nation.

Subject of Research: Clinical decision support tool for tuberculosis evaluation.
Article Title: TB or Not TB? A New Clinician Decision Support Tool for Tuberculosis.
News Publication Date: 2-Jan-2025.
Web References:
References: Dugdale, C. M., Zachary, K. C., Craig, R. L., Doms, A., Germaine, L., Green, C. V., Gulbas, E., Hurtado, R. M., Hyle, E. P., Jerry, M. S., Lazarus, J. E., Maxfield, S., Paras, M., Swanson, K., & Shenoy, E. S. (2025). TB or not TB? Development and validation of a clinical decision support system to inform airborne isolation requirements in the evaluation of suspected tuberculosis. Infection control and hospital epidemiology, 1–9. Advance online publication.
Image Credits:
Keywords: Tuberculosis, Clinical Decision Support, Infection Control, Healthcare Efficiency, Risk Assessment.